{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:46Z","timestamp":1793948446574,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00467-020-04609-0","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T02:03:16Z","timestamp":1592964196000},"page":"1397-1405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-6005","authenticated-orcid":false,"given":"Eugene Yu-hin","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"Tullus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"4609_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fped.2016.00039","volume":"4","author":"R Chanchlani","year":"2016","unstructured":"Chanchlani R, Parekh RS (2016) Ethnic differences in childhood nephrotic syndrome. Front Pediatr 4:39","journal-title":"Front Pediatr"},{"key":"4609_CR2","doi-asserted-by":"crossref","first-page":"I1800","DOI":"10.1136\/bmj.l1800","volume":"365","author":"N Webb","year":"2019","unstructured":"Webb N, Woolley R, Lambe T, Frew E, Brettell E, Barsoum E, Trompeter R, Cummins C, Deeks J, Wheatley K (2019) Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. Bmj 365:I1800","journal-title":"Bmj"},{"issue":"2","key":"4609_CR3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","volume":"21","author":"K Iijima","year":"2017","unstructured":"Iijima K, Sako M, Nozu K (2017) Rituximab for nephrotic syndrome in children. Clin Exp Nephrol 21(2):193\u2013202","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"4609_CR4","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19(7):794\u2013797","journal-title":"Pediatr Nephrol"},{"issue":"9950","key":"4609_CR5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet 384(9950):1273\u20131281","journal-title":"The Lancet"},{"issue":"9","key":"4609_CR6","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26(9):2259\u20132266","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4609_CR7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M (2014) Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25(4):850\u2013863","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4609_CR8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra T, Schaefer F (2018) Efficacy of rituximab vs. tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172(8):757\u2013764","journal-title":"JAMA Pediatr"},{"issue":"3","key":"4609_CR9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytu\u0142a","year":"2010","unstructured":"Prytu\u0142a A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R (2010) Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25(3):461\u2013468","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"4609_CR10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00431-017-2891-2","volume":"176","author":"G Desch\u00eanes","year":"2017","unstructured":"Desch\u00eanes G, Vivarelli M, Peruzzi L (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176(5):647\u2013654","journal-title":"Eur J Pediatr"},{"issue":"1","key":"4609_CR11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","volume":"31","author":"K Kamei","year":"2016","unstructured":"Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S (2016) Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol 31(1):89\u201395","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"4609_CR12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K (2013) Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 28(2):257\u2013264","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"4609_CR13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K (2011) Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 26(10):1823\u20131828","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4609_CR14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","volume":"30","author":"A Sinha","year":"2014","unstructured":"Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A (2014) Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transpl 30(1):96\u2013106","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4609_CR15","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2011","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L (2011) Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transpl 27(5):1910\u20131915","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4609_CR16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY-H Chan","year":"2020","unstructured":"Chan EY-H, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL-T, Yamamura T, Sinha A, Bagga A, Hogan J (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97(2):393\u2013401","journal-title":"Kidney Int"},{"issue":"4","key":"4609_CR17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","volume":"21","author":"S Fujinaga","year":"2017","unstructured":"Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T (2017) Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol 21(4):671\u2013676","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"4609_CR18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","volume":"34","author":"J Hogan","year":"2018","unstructured":"Hogan J, Dossier C, Kwon T, Macher M-A, Maisin A, Couderc A, Niel O, Baudouin V, Desch\u00eanes G (2018) Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 34(2):253\u2013259","journal-title":"Pediatr Nephrol"},{"key":"4609_CR19","doi-asserted-by":"crossref","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea. Medicine (Baltimore) 97(46)","DOI":"10.1097\/MD.0000000000013157"},{"issue":"4","key":"4609_CR20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","volume":"31","author":"H Webb","year":"2016","unstructured":"Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D (2016) Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome. Pediatr Nephrol 31(4):589\u2013594","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"4609_CR21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","volume":"34","author":"AP Maxted","year":"2019","unstructured":"Maxted AP, Dalrymple RA, Chisholm D, McColl J, Tse Y, Christian MT, Reynolds BC (2019) Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol 34(5):855\u2013863","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4609_CR22","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1542\/peds.2015-0486","volume":"136","author":"B Basu","year":"2015","unstructured":"Basu B, Mahapatra T, Mondal N (2015) Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics 136(1):e132\u2013e139","journal-title":"Pediatrics"},{"issue":"4","key":"4609_CR23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00431-012-1913-3","volume":"172","author":"S Fujinaga","year":"2013","unstructured":"Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y, Shimizu T, Kaneko K (2013) Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur J Pediatr 172(4):513\u2013518","journal-title":"Eur J Pediatr"},{"issue":"1","key":"4609_CR24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12882-018-1099-7","volume":"19","author":"T Horinouchi","year":"2018","unstructured":"Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K (2018) Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). BMC nephrol 19(1):302","journal-title":"BMC nephrol"},{"issue":"6","key":"4609_CR25","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bcp.13548","volume":"84","author":"A Bonanni","year":"2018","unstructured":"Bonanni A, Calatroni M, D'alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84(6):1238\u20131249","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4609_CR26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","volume":"35","author":"C Parmentier","year":"2019","unstructured":"Parmentier C, Delbet J-D, Decramer S, Boyer O, Hogan J, Ulinski T (2019) Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 35(3):455\u2013462","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"4609_CR27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-014-3034-x","volume":"30","author":"S Fujinaga","year":"2015","unstructured":"Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y, Shimizu T (2015) Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatr Nephrol 30(4):687\u2013691","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4609_CR28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00467-018-3900-z","volume":"33","author":"K Kamei","year":"2018","unstructured":"Kamei K, Ogura M, Sato M, Ito S, Ishikura K (2018) Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Pediatr Nephrol 33(6):1013\u20131018","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"4609_CR29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14740338.4.3.599","volume":"4","author":"Y Tsutsumi","year":"2005","unstructured":"Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4(3):599\u2013608","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"4609_CR30","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"M-C Chaumais","year":"2009","unstructured":"Chaumais M-C, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Desch\u00eanes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24(9):1753\u20131755","journal-title":"Pediatr Nephrol"},{"issue":"1-2","key":"4609_CR31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","volume":"30","author":"EJ Boren","year":"2008","unstructured":"Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME (2008) The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 30(1-2):90\u201398","journal-title":"J Autoimmun"},{"issue":"2","key":"4609_CR32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","volume":"47","author":"JC Gea-Banacloche","year":"2010","unstructured":"Gea-Banacloche JC (2010) Rituximab-associated infections. Seminars in hematology 47(2):187\u2013198","journal-title":"Seminars in hematology"},{"issue":"9","key":"4609_CR33","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","volume":"28","author":"A-L Sellier-Leclerc","year":"2013","unstructured":"Sellier-Leclerc A-L, Belli E, Gu\u00e9rin V, Dorfm\u00fcller P, Desch\u00eanes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28(9):1875\u20131879","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4609_CR34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","volume":"28","author":"M Sato","year":"2013","unstructured":"Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28(1):145\u2013149","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4609_CR35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ndt\/gfu258","volume":"30","author":"K Kamei","year":"2014","unstructured":"Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M, Ogura M, Ito S (2014) Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transpl 30(1):91\u201396","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"4609_CR36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000350681","volume":"226","author":"L Peuvrel","year":"2013","unstructured":"Peuvrel L, Chiffoleau A, Qu\u00e9reux G, Brocard A, Saint-Jean M, Batz A, Jolliet P, Dr\u00e9no B (2013) Melanoma and rituximab: an incidental association? Derm 226(3):274\u2013278","journal-title":"Derm"},{"issue":"4","key":"4609_CR37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/CMR.0000000000000074","volume":"24","author":"C Velter","year":"2014","unstructured":"Velter C, Pag\u00e8s C, Schneider P, Osio A, Brice P, Lebb\u00e9 C (2014) Four cases of rituximab-associated melanoma. Melanoma Res 24(4):401\u2013403","journal-title":"Melanoma Res"},{"issue":"7","key":"4609_CR38","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","volume":"29","author":"C Tarella","year":"2010","unstructured":"Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A (2010) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29(7):814\u2013824","journal-title":"J Clin Oncol"},{"key":"4609_CR39","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","volume":"10","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653","journal-title":"Front Immunol"},{"issue":"5","key":"4609_CR40","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/rheumatology\/key394","volume":"58","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H, Harper L, Kazmi MA, Kiani-Alikhan S, Li CK (2019) Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology 58(5):889\u2013896","journal-title":"Rheumatology"},{"issue":"11","key":"4609_CR41","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","volume":"32","author":"K Kamei","year":"2017","unstructured":"Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32(11):2071\u20132078","journal-title":"Pediatr Nephrol"},{"key":"4609_CR42","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s00467-019-04325-4","volume":"34","author":"B Basu","year":"2019","unstructured":"Basu B, Sander A, Preussler S, Sinha Mahapatra T, Schaefer F (2019) IPN11036-82 Long-term efficacy of rituximab & MMF maintenance - therapy in childhood SDNS. Abstracts of the 18th Congress of the International Pediatric Nephrology Association, Venice (Italy), October 2019. Pediatr Nephrol 34:1821\u20132260. https:\/\/doi.org\/10.1007\/s00467-019-04325-4","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"4609_CR43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.23876\/j.krcp.2017.36.3.257","volume":"36","author":"JH Kim","year":"2017","unstructured":"Kim JH, Park E, Hyun HS, Cho MH, Ahn YH, Choi HJ, Kang HG, Ha I-S, Cheong HI (2017) Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome. Kidney Res Clin Pract 36(3):257","journal-title":"Kidney Res Clin Pract"},{"issue":"12","key":"4609_CR44","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/nep.13554","volume":"24","author":"R Ramachandran","year":"2019","unstructured":"Ramachandran R, Bharati J, Rao I, Kashif AW, Nada R, Minz R, Gupta KL, Kohli HS (2019) Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. Nephrology (Carlton) 24(12):1241\u20131247","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"4609_CR45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00467-018-4139-4","volume":"34","author":"JD Delbet","year":"2019","unstructured":"Delbet JD, Leclerc G, Ulinski T (2019) Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery? Pediatr Nephrol 34(3):529\u2013532","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4609_CR46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","volume":"22","author":"M Sato","year":"2018","unstructured":"Sato M, Kamei K, Ogura M, Ishikura K, Ito S (2018) Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Clin Exp Nephrol 22(1):110\u2013116","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"4609_CR47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00467-017-3677-5","volume":"33","author":"M Colucci","year":"2018","unstructured":"Colucci M, Corpetti G, Emma F, Vivarelli M (2018) Immunology of idiopathic nephrotic syndrome. Pediatr Nephrol 33(4):573\u2013584","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4609_CR48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00467-018-4095-z","volume":"34","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Cascioli S, Serafinelli J, Emma F, Vivarelli M (2019) B cell phenotype in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol 34(1):177\u2013181","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4609_CR49","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rav\u00e0 L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27(6):1811\u20131822","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4609_CR50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000356439","volume":"38","author":"T Kimata","year":"2013","unstructured":"Kimata T, Hasui M, Kino J, Kitao T, Yamanouchi S, Tsuji S, Kaneko K (2013) Novel use of rituximab for steroid-dependent nephrotic syndrome in children. Am J Npehrol 38(6):483\u2013488","journal-title":"Am J Npehrol"},{"issue":"1","key":"4609_CR51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","volume":"34","author":"T Takahashi","year":"2019","unstructured":"Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, Ueno M, Kobayashi N, Uetake K, Nakanishi M (2019) Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatr Nephrol 34(1):87\u201396","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"4609_CR52","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00467-014-2794-7","volume":"29","author":"YH Ahn","year":"2014","unstructured":"Ahn YH, Kang HG, Lee JM, Choi HJ, Ha I-S, Cheong HI (2014) Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol 29(8):1461\u20131464","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"4609_CR53","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2215\/CJN.11941115","volume":"11","author":"C-Y Chan","year":"2016","unstructured":"Chan C-Y, Liu ID, Resontoc LP, Ng K-H, Chan Y-H, Lau PY-W, Than M, Jordan SC, Lam K-P, Yeo W-S (2016) T lymphocyte activation markers as predictors of responsiveness to rituximab among patients with FSGS. Clin J Am Soc Nephrol 11(8):1360\u20131368","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-020-04609-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T01:10:38Z","timestamp":1624497038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-020-04609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4609"],"URL":"https:\/\/doi.org\/10.1007\/s00467-020-04609-0","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"7 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}